LLY.BA Eli Lilly and Company
Company Analysis
Latest News
🟢 Eli Lilly is trading 4.27% up today amid healthcare rally as investors rotate from tech
Eli Lilly is trading at ARS 37,580.00, up 4.27%, amid a broader healthcare rally. - Healthcare stocks are up 2.12% during the regular session as investors...
Eli Lilly's Oral Weight-Loss Drug Foundayo Gains Key EU Recommendation
The European Medicines Agency’s advisory committee recommended Foundayo (orforglipron), Eli Lilly and Company’s once-daily oral GLP-1 treatment for obesity and...
🟢 Eli Lilly is trading 8.22% up today as investors rotate into healthcare
Eli Lilly is trading up 8.22% at ARS 36,320.00 as investors rotate into healthcare amid inflation and rate concerns weighing on technology stocks. - The...
🟢 Eli Lilly is trading 4.17% up today with healthcare-sector gains offering a possible tailwind
Eli Lilly is trading at ARS 34,960.00, up 4.17%, with healthcare-sector strength offering a possible tailwind. - Healthcare rose 1.64% during the regular...
Eli Lilly Could Reach $87 Billion in 2026 Revenue, Driven by Zepbound
Analysts expect Eli Lilly to generate up to $87 billion in revenue in 2026, supported largely by demand for its weight-loss drug Zepbound and its broader...
Eli Lilly Reports Positive Taltz-Zepbound Combo Results for Psoriasis, Obesity
Eli Lilly and Company reported positive results from its Phase 3b TOGETHER-PsO study of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with both...
🔴 Eli Lilly is trading at 4.68% down today as geopolitical and rate fears weigh on markets
Eli Lilly is trading 4.68% lower at ARS 32,620.00 as broad risk-off pressure from geopolitical and rate concerns weighs on markets and healthcare stocks. -...
🟢 Eli Lilly is trading 4.02% up amid healthcare sector gains
Eli Lilly is trading 4.02% higher at ARS 34,680.00 on October 7, 2026; no fresh company-specific announcement clearly explains the move. - Available coverage...
Eli Lilly Reports 23.3% Weight Loss With Experimental Combination Drug
At the European Association for the Study of Diabetes (EASD) conference, Eli Lilly reported that its oral GLP-1 drug Foundayo (orforglipron) was non-inferior...
Eli Lilly Reports Zepbound and Foundayo Outperform Rival Drugs
Eli Lilly announced positive results for two of its drugs at the European Association for the Study of Diabetes meeting. An indirect analysis found that...
Eli Lilly Secures FDA Approval for Onswik, Launches $6.5B Texas Factory
Eli Lilly received FDA approval for Onswik on September 24, 2026. This once-weekly basal insulin treats adults with type 2 diabetes. The medication reduces the...
Eli Lilly Wins FDA Approval for Breast Cancer Combo, Doubling Survival Time
The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Inluriyo-Verzenio combination for specific advanced breast cancers. The treatment targets...
Eli Lilly Upgraded to Strong-Buy, Berenberg Sees 25% Upside on Obesity Lead
Berenberg Bank upgraded Eli Lilly to Strong-Buy from Hold. The bank raised its price target, implying a potential 25% upside for the stock. Analysts expect...
Eli Lilly backs Caspian Therapeutics, aiming to regenerate the pancreas
Eli Lilly joined a $50 million investment in Caspian Therapeutics, a biotech startup spun out from Kura Oncology. The company develops small-molecule menin...
Eli Lilly buys Merida for $2.9B, diversifying beyond obesity and diabetes
Eli Lilly and Company signed a definitive agreement to acquire private biotech firm Merida Biosciences for up to $2.875 billion. The purchase price includes an...
Eli Lilly's Mounjaro Wins FDA Heart Approval, First Dual Agonist Claim
The U.S. Food and Drug Administration (FDA) approved Eli Lilly's Mounjaro to reduce major cardiovascular risks in adults with type 2 diabetes. This label...
Eli Lilly launches Foundayo in UK, marking first European oral pill debut
Eli Lilly launched its oral weight-loss and type 2 diabetes pill, Foundayo, in the United Kingdom on Monday. The UK is the first European country to offer the...
Eli Lilly Weekly Insulin Wins NICE Recommendation, Cutting Annual Injections by 85%
The National Institute for Health and Care Excellence (NICE) recommended Eli Lilly’s once-weekly insulin, Onswik (efsitora alfa), for NHS use in treating type...
🟢 Eli Lilly is trading 4.51% up today as Foundayo prescriptions rose 14%
Eli Lilly is trading 4.51% up at ARS 36140.00 after weekly prescriptions for oral obesity pill Foundayo climbed 14% to approximately 38,900, while Novo...
🟢 Eli Lilly is trading 5.0% up
Eli Lilly is trading at ARS 36,320.00, up 5.0% from a comparison close of ARS 34,580.00 during regular trading. This is a price-action follow-up, so a separate...